 Why is the division that reviews these post-transplant drugs interested in continuing to use the one-year endpoint or that endpoint when we know that perhaps it should be expanded? And we certainly know from patients that they feel that their quality of life could be improved if, in fact, there were other ways of dealing with this. Why hold on to that?